Vietnam's health sector completes comprehensive technology transfer from Japan for first strategic tech product to ‘reach finish line’ early

The Tam Anh General Hospital Group has become the first and only institution in Vietnam to be selected, on an exclusive basis, for the comprehensive transfer of core stem cell and immune cell technologies from a leading Japanese group, opening up new opportunities for treating cancer and chronic diseases and improving the health of people in Vietnam.

Mastering cell technology (stem cells and immune cells) to treat cancer, chronic diseases and intractable diseases is a national strategy approved by the government for implementation from 2026 to 2030. The comprehensive and in-depth transfer of core cell technology from Japan is good news: Vietnam has its first strategic technology product to "reach the finish line" early, with the technology transfer completed.

Comprehensive technology transfer

The technology transfer completion ceremony marks a new step forward for Tam Anh General Hospital in accessing and applying advanced processes in stem cell and immune cell technologies, ensuring compliance with Japanese standards at the highest level to improve the health of the Vietnamese people.

Japan is a global leader in the research, development, and application of stem cell and immune cell technologies.

As of 2026, Japan holds 3 Nobel Prizes in Physiology or Medicine from works directly related to these two fields, while pioneering the combination of immune cell therapy with existing cancer treatments to deliver superior effectiveness and prolong healthy life spans for patients.

With the ability to stimulate the body to self-repair "damaged" and "senescent" cells, stem cell and immune cell technologies are also expected to bring significant application potential in current healthcare and regenerative medicine.

With a modern infrastructure platform, a team of specialized experts and personnel, Tam Anh General Hospital has become Japan's exclusive partner in Vietnam for investment cooperation and comprehensive transfer of "core technologies" regarding stem cells and immune cells according to high-end standards.

Simultaneously, the Japanese side also comprehensively transfers valuable practical knowledge and experience in applying treatments for cancer, various dangerous chronic diseases, and advanced health care.

Prof. Dr. Matsuo Yoshinobu, a leading scientist at Grandsoul Group and Senior Technology Expert at the Grandsoul Nara Institute of Immunology, stated: "Tam Anh is the sole exclusive partner receiving comprehensive technology transfer in Vietnam. We are ready for both sides to jointly develop the field of safe, high-quality, and sustainable regenerative medicine in Vietnam, with treatment effectiveness and patient safety as top priorities."

The next-generation cell and immune cell technologies transferred this time were researched and developed by Grandsoul Group (Japan). These therapies have been officially licensed for application by the Japanese Ministry of Health, Labour and Welfare (MHLW) for many years, recording high efficacy and safety in treatment and healthcare.

The focus includes two main groups: the technology for isolation, culture, and selective differentiation of adipose tissue-derived mesenchymal stem cells (MSCs), and the technology for isolation, culture, and selective differentiation of natural killer (NK) cells for cancer treatment.

Mesenchymal stem cells open up potential in supporting the treatment of cardiovascular diseases, neurological disorders (stroke, dementia), diabetes, chronic obstructive pulmonary disease (COPD), and skin rejuvenation. Meanwhile, NK cell immunotherapy harnesses the immune system's ability to recognize and destroy cancer cells, adding another approach to the multimodal cancer treatment strategy alongside surgery, chemotherapy, radiotherapy, and targeted therapy.

From technology reception to self-reliance capacity

Prof. Dr. Ta Thanh Van, Chairman of the Professional Council of the Center for Regenerative Medicine & Cell Therapy at Tam Anh General Hospital in Hanoi, a leading Vietnamese expert in stem cells and immune cells, shared: "This is a significant milestone in the international medical integration process of the Tam Anh General Hospital System. People no longer need to incur high costs traveling to Japan and many other countries to access advanced cell therapies; from now on, right in Vietnam, there are synchronized technologies at a much more reasonable cost, ready to develop medical tourism."

Ngo Chi Dung, Chairman of the Board of Directors of Tam Anh General Hospital System, stated that the completion of the stem cell and immune cell technology transfer from Japan is a major milestone not only in medical cooperation between the two units but also in connecting technologies and establishing a network of experts for the common goal of public healthcare.

"We determine that this is not merely receiving the transfer of a brand-new technology and mastering the core technology in a field, but rather opening a strategic cooperation process between Tam Anh and its Japanese partners to jointly research, invest, and develop," he emphasized.

According to Ngo Chi Dung, the cell technologies are intended to be applied at five facilities of the Tam Anh General Hospital Group in Hanoi and Ho Chi Minh City, which handle more than 10,000 patient visits a day, helping reduce the costs of seeking treatment abroad while contributing to the development of medical tourism.